Slide 1: Lexaria Bioscience Corp. Investor Presentation December 2020
Lexaria Bioscience Corp. OTCQX:LXRP | LXX:CSE Drug Delivery Platform Innovator Investor Presentation December 2020 LexariaBioscience.com
Slide 2: Disclaimer
4 —, Syleare isclai x Disclaimer a This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 216 of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking stat
Slide 3: Lexaria Bioscience – Corporate Highlights
Focused on commercialization through partnerships and licensing Lexaria Bioscience – Corporate Highlights Disruptive, patented technology – designed for fast acting, less expensive & more effective oral drug delivery: Potential applications in: Antivirals (COVID-19, HIV and other infectious diseases
Slide 4: Key Executives, Directors and Advisors
Chris Bunka Chairman & CEO Serial entrepreneur involved in several private and public companies since the late 1980’s Extensive experience in the capital markets, corporate governance, M&A and finance Named inventor on multiple patent innovations John Docherty, M.Sc. President Specialist in developm
Slide 5: Patented DehydraTECH Drug Delivery
Patented DehydraTECH™ Drug Delivery Combine “API” with Fatty Acid Oil Speeds up onset Increases bioavailability Improves palatability API Apply to food / carrier particles Perform dehydration synthesis procedure Fatty Acid (e.g., LCFA) Sorbitol, Gum Arabic, etc. Render as powder or liquid for use in
Slide 6: How Does DehydraTECH Work?
Fatty acids are believed to block and shunt bound APIs away from bitter taste receptors1 Small intestine quickly absorbs LCFAs into lymphatics (bypassing first pass liver effect) and MCFAs via the liver3 Lipids enable gastric protection and rapid passage2 How Does DehydraTECH™ Work? Close collaborat
Slide 7: DehydraTECH – Patented Technology Potential Benefits
Reduces Drug Administration Costs Increases bioavailability Improves speed of onset Masks unwanted taste* Eliminates the need for sugar-filled edibles Much more effective at delivering drug into bloodstream*** Effects are felt in minutes** Higher ratio of drug delivery expected to lower overall drug
Slide 8: Growing Markets
Growing Markets 2017 2025 $900B $510B 6.9% CAGR OTCQX:LXRP | LXX:CSE Global Drug Delivery Systems Market https://www.transparencymarketresearch.com/drug-delivery-systems-market.html https://www.grandviewresearch.com/industry-analysis/controlled-release-drug-delivery-market Becton, Dickinson & Compan
Slide 9: Major Product Development Pipeline Opportunities
Major Product Development Pipeline Opportunities OTCQX:LXRP | LXX:CSE POC = Proof-of-concept
Slide 10: DehydraTECH for Cannabinoids - Faster and More Effective Delivery
10 90mg DehydraTECH dose vs. Competitor 100mg dose Competitor delivers virtually zero CBD at 30 minutes Lexaria quicker “on” and quicker “off” 1. Inhalation High bioavailability (~27%1), harmful to Lungs 2. Sub-lingual (under tongue) Medium bioavailability (~13%2), foul taste 3. Oral – Gastrointesti
Slide 11: Case Study: TurboCBD - Clinically Demonstrated Blood/Body Response Benefits
Case Study: TurboCBD™ - Clinically Demonstrated Blood/Body Response Benefits 2018 European human clinical study (n=12) Double-blind, 90 mg CBD dose 317% more CBD delivered ≤ 30 min (only TurboCBD 90 > placebo; p<0.05) Higher CBD delivery throughout entire study Lower blood pressure shown vs. baselin
Slide 12: Significant BP Reduction and Cerebral Perfusion
Significant BP Reduction and Cerebral Perfusion OTCQX:LXRP | LXX:CSE
Slide 13: Hypertension Affects More Than a Billion People / Year
Hypertension Affects More Than 1 Billion People / Year Common side effects of current hypertension treatments include:* Potassium loss Respiratory effects Dizziness and weakness Reduced kidney function OTCQX:LXRP | LXX:CSE Lexaria is researching CBD-based treatments that may have fewer side effects:
Slide 14: Revenue Generation Underway and Growing in Cannabinoid Sector
Revenue Generation Underway and Growing in Cannabinoid Sector OTCQX:LXRP | LXX:CSE Wholly-owned subsidiary Lexaria Hemp Corp. generates revenues from DehydraTECH-enabled CBD powders via its licensees and fee-for-service clientele; Lexaria announced that it had received purchase-order commitments for
Slide 15: Nicotine – $814 Billion Global Mega-Market
* https://www.who.int/news-room/fact-sheets/detail/tobacco **https://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/tobacco_related_mortality/index.htm NICOTINE – $814 Billion Global Mega-Market Smoking is the world’s leading cause of preventable death Although nicotine is not a beni
Slide 16: DehydraTECH Science – Oral Nicotine Delivery
Blood sampling T=0, 15, 30, 45, 60, 120, 240 and 480 min 48% improvement in peak Cmax nicotine delivery to the bloodstream relative to controls 1,160% faster delivery of equivalent peak Cmax quantities of nicotine to the bloodstream than achieved with controls (within 15 min vs. 2.9 hours) 560% high
Slide 17: Strategic Licensing – Oral Nicotine Delivery
Strategic Licensing – Oral Nicotine Delivery January 2019: License and funding to test ingestible/oral nicotine products International licence rights Undisclosed royalty on any oral nicotine product sales utilizing DehydraTECH Oral Nicotine (Non-Smoking Alternative) 68% of U.S. smokers wish to quit;
Slide 18: Target Infectious Disease Drug Classes – COVID-19, HIV & Other Viral Diseases
Target Infectious Disease Drug Classes – COVID-19, HIV & Other Viral Diseases Vaccines Antiviral Drugs Antiretroviral Drugs Protease Inhibitors Fusion Inhibitors Nucleoside, Non- Nucleoside & Nucleotide Reverse Transcriptase Inhibitors General Antiviral (Non-Retro) Nucleoside and Nucleotide Analogs
Slide 19: COVID-19 (SARS-CoV-2) Antiviral Research
COVID-19 (SARS-CoV-2) Many oral antivirals are poorly absorbed fat soluble drugs which compromises potency and are exceptionally expensive – limiting dosing capability Present Antiviral Therapy Landscape Antiviral therapies are being investigated to potentially fight infection Oral antiviral therapi
Slide 20: DehydraTECH Science – Oral Antiviral Delivery
DehydraTECH Science – Oral Antiviral Delivery OTCQX:LXRP | LXX:CSE December 2020: Rodent PK study completed (n=40) demonstrating significant enhancement in antiviral drug delivery using DehydraTECH; Two drugs studied (darunavir and efavirenz) from representative classes of antiviral compounds under
Slide 21: Corporate and Financial Information
Corporate and Financial Information www.LexariaBioscience.com Product Licensing & Investor Inquiries: info@LexariaBioscience.com OTCQX:LXRP | LXX:CSE *as of 12/29/2020, source BigCharts
Slide 22: Investment Catalysts/Highlights
Investment Catalysts/Highlights Disruptive drug delivery technology with multiple opportunities for success in antivirals, nicotine, cannabinoids, other APIs; Investigation planned or underway with CBD for hypertension, antivirals for COVID-19 and other infectious diseases, and for nicotine; Rapidly
Slide 23: Lexaria Bioscience Corp. Contact
Lexaria Bioscience Corp. LXRP:US | LXX:CSE Drug Delivery Platform Innovator 866.221.3341 IR@lexariabioscience.com LexariaBioscience.com CONTACT:
Slide 24: Scientific Appendix
Scientific Appendix OTCQX:LXRP | LXX:CSE
Slide 25: Example Nicotine Blood Absorption Data
Example Nicotine Blood Absorption Data NOTE: No AEs reported. p Value < 0.05 signifies statistical significance OTCQX:LXRP | LXX:CSE
Slide 26: Nicotine Brain Tissue PK Data Highlighted
Nicotine Brain Tissue PK Data Highlighted 17LEXAP1 - Study of 12 lab rats with Brain Testing at 24 hours April 2018 18LEXAP1 - Study of 40 lab rats with Brain Testing at 1, 4, 8 and 24 hours August 2018 OTCQX:LXRP | LXX:CSE
Slide 27: Nicotine NMR Analyses (T=0)
Nicotine NMR Analyses (T=0) No chemical shift apparent ruling out covalent bonded new chemical compound OTCQX:LXRP | LXX:CSE
Slide 28: 2018 TurboCBD Clinical Study
2018 TurboCBD™ Clinical Study OTCQX:LXRP | LXX:CSE
Slide 29: DehydraTECH Enhancement Underway
DehydraTECH Enhancement Underway 19LEXAP1 (05/19) Design: DehydraTECH CBD (with & without an intestinal absorption “enhancement” ingredient incorporation) vs. MCT-based CBD positive control Enhancement Ingredient is on FDA GRAS List 25 mg/Kg (oral gavage) Standard DehydraTECH formulation: CBD + sunf
Slide 30: Thank you
Thank you OTCQX:LXRP | LXX:CSE